Title
Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology
Authoring Organizations
Publication Month/Year
May 22, 2024
Last Updated Month/Year
September 30, 2024
Supplemental Implementation Tools
Document Type
Other
Country of Publication
US
Document Objectives
To update the ASCO-Oncology Nursing Society (ONS) standards for antineoplastic therapy administration safety in adult and pediatric oncology and highlight current standards for antineoplastic therapy for adult and pediatric populations with various routes of administration and location.
Target Patient Population
Adult and pediatric patients with cancer receiving antineoplastic therapy.
Target Provider Population
Nonprofessional caregivers of patients with cancer.
PICO Questions
What are standards for ordering, preparing, dispensing, and administering antineoplastic therapy?
Does the care provided by oncology professionals who meet certain qualifications result in fewer medical errors and reduce preventable harm, compared with those who do not?
Does the care provided by health care organization that have specific quality improvement or standardization of care policies in place result in fewer medical errors and reduce preventable harm compared with no or less specific policies?
Do documentation policies mandated and/or implemented by health care organizations result in fewer medical errors and reduce preventable harm compared with no documentation policies?
Do policies on treatment planning, patient consent, and patients' education result in fewer medical errors and reduce preventable harm, compared with those who do not?
Do policies on ordering, preparing, dispensing, and administering antineoplastic therapy result in fewer medical errors and reduce preventable harm, compared with no or less specific policies?
Do policies on ordering, preparing, dispensing, and administering antineoplastic therapy for patients at home result in fewer medical errors, reduce preventable harm, and increase adherence, compared with no or less specific policies?
Do policies on ordering, preparing, dispensing, and administering antineoplastic therapy intrathecally or intraventricularly for patients result in fewer medical errors and reduce preventable harm, compared with those who do not?
Do policies on post-treatment monitoring of adverse events from antineoplastic therapy result in fewer medical errors and reduce preventable harm, compared with no or less specific policies?
Inclusion Criteria
Male, Female, Adolescent, Adult, Child, Infant, Older adult
Health Care Settings
Ambulatory, Home health, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, community pharmacist, health systems pharmacist, pharmacy technician, physician, physician assistant
Scope
Treatment, Management, Prevention
Diseases/Conditions (MeSH)
D002173 - Cancer Care Facilities, D000903 - Antibiotics, Antineoplastic, D000964 - Antimetabolites, Antineoplastic, D000970 - Antineoplastic Agents, D018906 - Antineoplastic Agents, Alkylating, D000074322 - Antineoplastic Agents, Immunological, D000972 - Antineoplastic Agents, Phytogenic, D000971 - Antineoplastic Combined Chemotherapy Protocols, D024221 - Antineoplastic Protocols
Keywords
antineoplastic agents, standards, antineoplastic therapy
Source Citation
Siegel RD, LeFebvre KB, Temin S, et al. Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards. JCO Oncol Pract. 2024 May 22. doi: 10.1200/OP.24.00216.